⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 14, 2026Alimentary Pharmacology & TherapeuticsOpen Access

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation

Ellen Werner Maria C B van Hooff Gemma Weijsters Maria A. van de Vrie Rozanne C. de Veer U. Beuers Joost P.H. Drenth Frans J.C. Cuperus Remco van Dijk Bart J. Veldt Michael Klemt‐Kropp Suzanne van Meer Robert C. Verdonk Hajo J. Flink Jan Maarten Vrolijk Matthijs Kramer Cyriel Y. Ponsioen Kirsten Boonstra Femke Boersma Hendrik J. M. de Jonge Frank H.J. Wolfhagen L.C. Baak Susanne L. Onderwater Jeroen D. van Bergeijk Paul G. van Putten G.J. de Bruin Rob P. R. Adang Maria N. Aparicio‐Pages Wink de Boer Frank ter Borg Hanneke van Soest E de Vries Nicole S. Erler Bettina E. Hansen H Janssen Adriaan J. van der Meer the Dutch PBC Study Group

View Full Paper

Ask AI

Bookmark

Share

Key Points

Assess the dosing of UDCA in Dutch patients with primary biliary cholangitis and identify optimization opportunities.
Nationwide assessment of therapy uptake
Analysis of UDCA dosing patterns
Comparison of dosing based on biochemical response and body weight
UDCA was often insufficiently dosed in patients.
Opportunities exist for optimizing treatment in patients with better biochemical responses.
Patients with higher body weight may benefit from adjusted dosing.

Implication

Analyses indicate optimization of first-line anticholestatic therapy in patients with primary biliary cholangitis, highlighting treatment opportunities.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Werner et al. (2026) studied this question.

synapsesocial.com/papers/69e07cfa2f7e8953b7cbe048 https://doi.org/10.1111/apt.70669

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Beyond the Surface: Unveiling Hidden Hurdles to Primary Biliary Cholangitis Care2024 · 1 citations
2Clinical characteristics of newly diagnosed patients with primary biliary cholangitis (PBC) indicate the need for better awareness on timely diagnosis and adequate UDCA therapyOriginal Research · 2025
3Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis2024 · 17 citations
4Optimizing Care in Primary Biliary Cholangitis: Current Treatments and the Second-Line Decision2025
5Advancing care in primary biliary cholangitis: emerging insights and novel therapiesHuman Clinical Trial · 2025